Tomer Mark, MD

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Tomer Mark, MD, discusses establishing minimal residual disease (MRD) as a surrogate marker for survival in multiple myeloma.